J&J's depression drug Spravato hits $1B in 2024 sales, up 56% from 2023, with expanded label approval and 140,000+ patients ...

One of Inhibrx Biosciences’ antibody candidates has shown encouraging early efficacy in colorectal cancer. But its safety is ...

Just over 20 years ago, the people of California voted to spend billions of dollars on an exciting new idea to remake ...